| Bioactivity | TGX-155 (AZ12649385) is a selective inhibitor of PI3Kβ. TGX-155 has potential applications in antithrombotic therapy[1][2][3]. |
| In Vivo | TGX-155 (1.5 mg/kg 和 2.5 mg/kg；静脉注射；单剂量) 以时间和剂量依赖性方式显著改善了兔颈动脉损伤中的循环血流量减少 (CFRs)[3]。 |
| Name | TGX-155 |
| CAS | 351071-90-4 |
| Formula | C20H19FN2O3 |
| Molar Mass | 354.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Verheijen J C, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs[J]. Drugs Future, 2007, 32(6): 537-547. [2]. Nylander S, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. [3]. Sturgeon SA, et al. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods. 2006 Jan-Feb;53(1):20-9. |